A recent study highlights how DNA microarray technology enables high-throughput gene analysis, supporting variation detection, expression profiling, and clinical research. By refining probe design and ...

Each month, The Clinical Advisor makes one new clinical feature available ahead of print. Don’t forget to take the poll. The results will be published in the next month’s issue. Healthcare providers ...

Nucleus Genomics, the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone. DNA and ...

Nucleus Genomics, the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone. DNA and ...

Most comprehensive and ethnically diverse genomic coverage on a high throughput microarray delivers multi-disease and pharmacogenomic research analysis across global populations CARLSBAD, ...

Please provide your email address to receive an email when new articles are posted on . The study included 250 patients with epilepsy. A history of delayed development and earlier seizure onset were ...

Join us for an insightful webinar on the use of polygenic risk scores (PRS) for cardiovascular disease (CVD). The analysis of genetic variation across large populations plays a crucial role in ...

It wasn’t all that long ago that we cracked the human genome, and in just a few short years we became used to direct-to-consumer genetic sequencing companies, like Ancestry.com and 23&Me, which could ...

Designation highlights GeneDx innovation in clinical whole genome and whole exome testing and accelerates the pathway for FDA authorization of these novel diagnostic tests GeneDx (Nasdaq: WGS), a ...

NEW YORK--(BUSINESS WIRE)--Nucleus Genomics, a next-generation consumer genetic testing and analysis company, has raised $14 million in a new funding round led by Alexis Ohanian's Seven Seven Six. The ...